Latest Breaking News On - Conditionally active biologic - Page 1 : comparemela.com

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeSan diegoCostantine albanyMatthew taylorVineet kwatraJennifer eva selfridgeJacob stephen thomasInderjit mehmiBruce mackleKartik aysolaJudith llorin sangalangRichard waldronOmid hamidAmerican society of clinical oncologyBioatla inc

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - BioAtla (NASDAQ:BCAB)

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the

United statesMccormick placeSan diegoRichard waldronBruce mackle lifesci advisorsBioatla incAmerican society of clinical oncologyMccormick place convention centerConditionally active biologicClinical oncologyAnnual meetingConditionally active biologicsRichard waldron chief financial officer bioatla

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoRichard waldronOzuriftamab vedotinMecbotamab vedotinBruce mackleLifesci advisorsBioatla incAmerican association for cancer researchRare cancers congressOffice of orphan products developmentExchange commissionConditionally active biologicChief executive officerOperational updatesRare cancers

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data.

United statesSan diegoRichard waldronMecbotamab vedotinOzuriftamab vedotinBruce mackleRare cancers congressBioatla incAmerican association for cancer researchExchange commissionLifesci advisorsOffice of orphan products developmentConditionally active biologicChief executive officerOperational updatesRare cancers

BioAtla to Participate in the 42nd Annual J P Morgan Healthcare Conference

BioAtla to Participate in the 42nd Annual J P Morgan Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesSan diegoRichard waldronBruce mackleBioatla incLifesci advisorsConditionally active biologicHealthcare conferenceConditionally active biologicsSci advisors